Research programme: protease inhibitors - Plexxikon
Latest Information Update: 06 Apr 2011
At a glance
- Originator Plexxikon
- Class Small molecules
- Mechanism of Action Renin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hypertension
Most Recent Events
- 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
- 15 Apr 2010 Preclinical development is ongoing with Plexxikon
- 05 Mar 2008 This programme is still in active development